BRUSSELS, Belgium - Boehringer Ingelheim and Ablynx have come together on a $265 million deal to explore the use of Ablynx' novel class of therapeutic proteins - nanobodies - in treatments for Alzheimer's disease. Andreas Barner, Boehringer Ingelheim's vice chairman and head of pharma research, described it as a "powerful and unique technology." (BioWorld International)

BRUSSELS, Belgium - Boehringer Ingelheim and Ablynx have come together on a $265 million deal to explore the use of Ablynx' novel class of therapeutic proteins - nanobodies - in treatments for Alzheimer's disease. Andreas Barner, Boehringer Ingelheim's vice chairman and head of pharma research, described it as a "powerful and unique technology." (BioWorld International)

BRUSSELS, Belgium - The London-based European Medicines Agency is expecting a high level of activity in 2007, and much of the work is likely to come from evaluation of new biotechnology medicine applications. (BioWorld International)

BRUSSELS, Belgium - The London-based European Medicines Agency is expecting a high level of activity in 2007, and much of the work is likely to come from evaluation of new biotechnology medicine applications. (BioWorld International)

BRUSSELS, Belgium - The European Union's Christmas present to the biotechnology industry was a Dec. 22 announcement of €628 million ($750 million) funding for health research in 2007. Individual grants of up to €12 million are being made available for projects across a broad range of biotechnology and human health. (BioWorld International)

BRUSSELS, Belgium - The European Union's Christmas present to the biotechnology industry was a Dec. 22 announcement of €628 million ($750 million) funding for health research in 2007. Individual grants of up to €12 million are being made available for projects across a broad range of biotechnology and human health. (BioWorld International)